OBR Daily Commentary

forumImage

Kidney Cancer Progression Linked to Shifts in Tumor Metabolism

(NCI) June 24, 2013 - Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: June 24, 2013)

quotesThe TCGA findings offer new insights into why some kidney cancers are more aggressive and presents opportunities to develop therapeutics addressing these findings. The metabolic shift in some tumors may explain their aggressiveness. The authors note that the PI3K/AKT/mTOR pathway may be especially important in this metabolic shift. Caution must always be considered in these findings because to date the benefits of targeting this pathway have not met with the robust benefits that might be suggested by the TCGA analysis. Future efforts may suggest additional targets that might offer the poor risk patients better options. It may also help to define the at risk populations of patients following potentially curative surgery who might benefit from additional treatment options.quotes

Add Comment 1 Comment
forumImage

Analysis: New Cancer Breakthroughs Add Pressure to Control Costs

(Reuters) June 5, 2013 - An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers and insurers will be under pressure to find savings elsewhere to pay for the high price tags of the new treatments.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: June 05, 2013)

quotesA new model for the delivery of the most promising therapies to cancer patients is mandatory. As this article points out we may well be on the brink of additional major breakthroughs in cancer care. Just having returned from the 2013 ASCO meeting in Chicago, we must solve the delivery of this potential on behalf of future cancer patients. Rather than a N.I.C.E type of solution we must identify ways to incentivize industry to deliver the best possible outcomes, while recognizing that a patient and their insurance company do not have infinite resources. An option would be to create a "Value" proposition for all diseases, and set benchmarks that must be met than when successful compensate sponsors appropriately when compared to me-too drugs that are incremental in their approach and benefit. We need breakthrough treatments, not next generation me-too drugs that offer little new.quotes

Add Comment 1 Comment
forumImage

Mayo Clinic Finds Experimental Drug Inhibits Growth in All Stages of Common Kidney Cancer

(Mayo Clinic) Apr 30, 2013 - Researchers at Mayo Clinic's campus in Florida have discovered a protein that is overly active in every human sample of kidney cancer they examined.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: May 01, 2013)

quotesThe next generation of agents targeting clear cell carcinoma of the kidney will certainly come from a better understanding of the biology and novel targets that when inhibited could benefit patients. This is especially true for targets and agents that are different than our currently available treatments that target the VEGF and mTOR pathways. These authors suggest a novel target, SCD1,the protein that is expressed from its activation, the ability of a agent A939572 to interfere with its action, and when combined with an mTOR inhibitor synergistic activity was demonstrated. This pathway and this class of agents are certainly ready to take to the clinic when the appropriate preclinical toxicology is complete. As for most next generation agents in ccRCCa they will be combined with currently available agents. As such phase 1 trials should be both single agent as well as combinations of agents to speed the discovery process. Additionally, a companion diagnostic would speed the discovery process if it is determined that only some patients with ccRCCA express this genetic abnormality.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...